Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMVQW8)

Drug Name	PMID25470667-Compound-Figure4-1A Drug Info
Cross-matching ID	TTD Drug ID DMMVQW8

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Diacylglycerol acyltransferase 1 (DGAT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[2]
LCQ908	DMFLJHQ	Familial chylomicronemia syndrome	5C80	Phase 3	[3]
AZD7687	DMS9I6A	Diabetic complication	5A2Y	Phase 1	[4]
P-7435	DMNZQU5	Diabetic complication	5A2Y	Phase 1	[5]
Azole derivative 7	DMVUJGI	N. A.	N. A.	Patented	[1]
Carbamide derivative 3	DM4ISCQ	N. A.	N. A.	Patented	[1]
T863	DMX41ZF	Discovery agent	N.A.	Patented	[1]
Benzamide derivative 19	DM5YNTM	N. A.	N. A.	Patented	[1]
Lactam derivative 5	DMX5FYZ	N. A.	N. A.	Patented	[1]
Pyridine-carboximide derivative 2	DMHXWZB	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Diacylglycerol O-acyltransferase 2 (DGAT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vitamin B3	DMQVRZH	Chronic renal failure	GB61.Z	Approved	[6]
ARI-3037MO	DM9LNXS	Cardiovascular disease	BA00-BE2Z	Phase 2	[7]
PF-06865571	DMZE3GK	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[8]
PF-06427878	DMGB32Z	Cardiovascular disease	BA00-BE2Z	Phase 1	[9]
PMID25470667-Compound-roselipins	DMCF2G7	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Diacylglycerol acyltransferase 1 (DGAT1)	TTF8P9I	DGAT1_HUMAN	Inhibitor	[1]
Diacylglycerol O-acyltransferase 2 (DGAT2)	TTRHEQ4	DGAT2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
2	In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids from Sophora flavescens. Planta Med. 2004 Mar;70(3):258-60.
3	DGAT1 inhibitors as anti-obesity and anti-diabetic agents. Curr Opin Drug Discov Devel. 2010 Jul;13(4):489-96.
4	Clinical pipeline report, company report or official report of AstraZeneca (2011).
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033014)
6	Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
7	2011 Pipeline of Arisaph Pharmaceuticals.
8	Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis. J Med Chem. 2022 Nov 24;65(22):15000-15013.
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)